Boston Scientific Corp. BSX
i
Market dataready · fetched 2026-11-07T21:28:56.879Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:56:20.066299095Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T21:28:56.371135+00:00
Boston Scientific Corp. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 45.05 | 45.3% | 5.9% | 41.03 | 41.0% | 4.7% |
| 25Δ | 44.59 | 44.7% | 5.0% | 41.35 | 42.0% | 4.2% |
| 30Δ | 44.22 | 45.0% | 4.4% | 41.65 | 44.1% | 3.8% |
| 35Δ | 43.85 | 44.3% | 3.8% | 41.93 | 47.0% | 3.5% |
| 40Δ | 43.48 | 41.9% | 3.1% | 42.26 | 45.7% | 3.0% |
| 45Δ | 43.19 | 43.7% | 2.8% | 42.60 | 44.2% | 2.5% |
| 50Δ | 42.90 | 45.3% | 2.5% | 42.91 | 45.7% | 2.2% |
| 55Δ | 42.58 | 46.8% | 2.2% | 43.20 | 44.5% | 1.8% |
| 60Δ | 42.22 | 49.5% | 1.9% | 43.48 | 42.1% | 1.4% |
| 65Δ | 41.82 | 52.4% | 1.7% | 43.83 | 43.4% | 1.2% |
| 70Δ | 41.37 | 55.0% | 1.5% | 44.34 | 48.3% | 1.1% |
| 75Δ | 40.41 | 71.8% | 1.5% | 44.78 | 49.2% | 0.9% |
| 80Δ | 39.65 | 75.7% | 1.2% | 45.14 | 46.7% | 0.6% |
20Δ
- Pseudo strike
- 45.05
- IV
- 45.3%
- B/E move
- 5.9%
- Pseudo strike
- 41.03
- IV
- 41.0%
- B/E move
- 4.7%
25Δ
- Pseudo strike
- 44.59
- IV
- 44.7%
- B/E move
- 5.0%
- Pseudo strike
- 41.35
- IV
- 42.0%
- B/E move
- 4.2%
30Δ
- Pseudo strike
- 44.22
- IV
- 45.0%
- B/E move
- 4.4%
- Pseudo strike
- 41.65
- IV
- 44.1%
- B/E move
- 3.8%
35Δ
- Pseudo strike
- 43.85
- IV
- 44.3%
- B/E move
- 3.8%
- Pseudo strike
- 41.93
- IV
- 47.0%
- B/E move
- 3.5%
40Δ
- Pseudo strike
- 43.48
- IV
- 41.9%
- B/E move
- 3.1%
- Pseudo strike
- 42.26
- IV
- 45.7%
- B/E move
- 3.0%
45Δ
- Pseudo strike
- 43.19
- IV
- 43.7%
- B/E move
- 2.8%
- Pseudo strike
- 42.60
- IV
- 44.2%
- B/E move
- 2.5%
50Δ
- Pseudo strike
- 42.90
- IV
- 45.3%
- B/E move
- 2.5%
- Pseudo strike
- 42.91
- IV
- 45.7%
- B/E move
- 2.2%
55Δ
- Pseudo strike
- 42.58
- IV
- 46.8%
- B/E move
- 2.2%
- Pseudo strike
- 43.20
- IV
- 44.5%
- B/E move
- 1.8%
60Δ
- Pseudo strike
- 42.22
- IV
- 49.5%
- B/E move
- 1.9%
- Pseudo strike
- 43.48
- IV
- 42.1%
- B/E move
- 1.4%
65Δ
- Pseudo strike
- 41.82
- IV
- 52.4%
- B/E move
- 1.7%
- Pseudo strike
- 43.83
- IV
- 43.4%
- B/E move
- 1.2%
70Δ
- Pseudo strike
- 41.37
- IV
- 55.0%
- B/E move
- 1.5%
- Pseudo strike
- 44.34
- IV
- 48.3%
- B/E move
- 1.1%
75Δ
- Pseudo strike
- 40.41
- IV
- 71.8%
- B/E move
- 1.5%
- Pseudo strike
- 44.78
- IV
- 49.2%
- B/E move
- 0.9%
80Δ
- Pseudo strike
- 39.65
- IV
- 75.7%
- B/E move
- 1.2%
- Pseudo strike
- 45.14
- IV
- 46.7%
- B/E move
- 0.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 37.47% | |
| 37.62% | |
| 37.59% | |
| 35.85% | |
| 34.24% | |
| 33.93% | |
| 35.73% | |
| 36.66% | |
| 38.67% | |
| 35.98% | |
| 39.28% | |
| 37.72% | |
| 40.37% | |
| 37.98% | |
| 36.38% | |
| 46.01% | |
| 40.71% | |
| 39.87% | |
| 49.88% | |
| 42.84% | |
| 45.59% | |
| 41.13% | |
| 37.81% | |
| 33.82% | |
| 37.72% | |
| 40.38% | |
| 38.29% | |
| 38.28% | |
| 34.89% | |
| 38.98% | |
| 37.53% | |
| 38.19% | |
| 37.52% | |
| 33.44% | |
| 37.47% | |
| 37.07% | |
| 36.99% | |
| 38.57% | |
| 36.73% | |
| 39.25% | |
| 39.51% | |
| 39.14% | |
| 42.17% | |
| 42.90% | |
| 44.57% | |
| 46.27% | |
| 47.95% | |
| 50.29% | |
| 49.97% | |
| 53.40% | |
| 55.91% | |
| 56.93% | |
| 65.26% | |
| 62.74% | |
| 70.29% | |
| 74.17% | |
| 52.89% | |
| 47.43% | |
| 42.63% |
Medical Devices
BVS
Description unavailable
More →BWAY
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company…
More →CATX
Perspective Therapeutics Inc. (CATX) is a pioneering biotechnology firm focused on revolutionizing cancer care through the development of innovative radiopharmaceuticals.…
More →CBLL
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company is headquartered in…
More →CERS
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in…
More →CLPT
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
More →